Predictive utility of cyclo-oxygenase-2 expression by colon and rectal cancer |
| |
| Authors: | Kristel C. Lobo Prabhu Lan Vu Simon K. Chan Terry Phang Allen Gown Steven J. Jones Sam M. Wiseman |
| |
| Affiliation: | 1. Department of Surgery, St Paul''s Hospital and University of British Columbia, Room C303, Burrard Building, 1081 Burrard Street, Vancouver, British Columbia, Canada;2. Department of Medical Genetics, University of British Columbia and Michael Smith Genome Sciences Center, British Columbia Cancer Research Center, Vancouver, British Columbia, Canada;3. Department of Pathology and Lab Medicine, University of British Columbia, Vancouver, British Columbia, Canada;4. PhenoPath Laboratories, Seattle, WA, USA |
| |
| Abstract: | ![]()
BackgroundCyclo-oxygenase-2 (COX-2), an inducible enzyme expressed in areas of inflammation, is a target of interest for colorectal cancer therapy. Currently, the predictive significance of COX-2 in colorectal cancer remains unclear.MethodsTissue microarrays were constructed using 118 colon cancer and 85 rectal cancer specimens; 44 synchronous metastatic colon cancer and 22 rectal cancer lymph nodes were also evaluated. COX-2 expression was assessed by immunohistochemistry. Univariate analysis was used to determine the predictive significance of clinicopathologic variables. Overall survival, disease-specific survival, and disease-free survival were the main outcomes examined.ResultsCOX-2 was found to be expressed in 93% of colon cancers and 87% of rectal cancers. Decreased COX-2 expression was related to decreased disease-specific survival (P = .016) and decreased disease-free survival (P = .019) in the rectal cancer cohort but not in the colon cancer cohort.ConclusionsCOX-2 expression has predictive utility for management of rectal but not colon cancer. |
| |
| Keywords: | Cyclo-oxygenase-2 Colon cancer Rectal cancer Colorectal cancer Immunohistochemistry |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
